Intelligence Feed event · Macro · 2026-08-30

    Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026

    Question

    Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026

    Direct answer

    Cytokinetics released additional clinical findings for aficamten (MYQORZO) during a late-breaking clinical trial session at the European Society of Cardiology (ESC) Congress 2026. Results from the ACACIA-HCM study showed aficamten delivered measurable improvements in diastolic function and cardiac structure beyond baseline exercise capacity in non-obstructive HCM patients, supporting broader therapeutic utility.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026”, revision 1, evidence through 2026-08-30. https://marketontology.com/market-events/2026-08-30/cytokinetics-presents-late-breaking-aficamten-data-at-esc-congress-2026-47f670

    MACRO
    Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026
    Cytokinetics released additional clinical findings for aficamten (MYQORZO) during a late-breaking clinical trial session at the European Society of Cardiology (ESC) Congress 2026. Results from the ACACIA-HCM study showed aficamten delivered measurable improvements in diastolic function and cardiac structure beyond baseline exercise capacity in non-obstructive HCM patients, supporting broader therapeutic utility.
    CYTK
    Impact
    72
    AUG 30
    SIG
    88%
    CYTK
    Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026
    Cytokinetics released additional clinical findings for aficamten (MYQORZO) during a late-breaking clinical trial session at the European Society of Cardiology (ESC) Congress 2026. Results from the ACACIA-HCM study showed aficamten delivered measurable improvements in diastolic function and cardiac structure beyond baseline exercise capacity in non-obstructive HCM patients, supporting broader therapeutic utility.
    → Positive late-breaking clinical readout expands the addressable patient population for aficamten into non-obstructive HCM, enhancing CYTK commercial valuation.
    Impact
    Cytokinetics released additional clinical findings for aficamten (MYQORZO) during a late-breaking clinical trial session at the European Society of Cardiology (ESC) Congress 2026. Results from the ACACIA-HCM study showed aficamten delivered measurable improvements in diastolic function and cardiac structure beyond baseline exercise capacity in non-obstructive HCM patients, supporting broader therapeutic utility.
    Affected
    CYTK
    Transmission
    Positive late-breaking clinical readout expands the addressable patient population for aficamten into non-obstructive HCM, enhancing CYTK commercial valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CYTKclinical pipeline de-risking and market expansionUp1-5dLate-breaking trial presentation at ESC Congress 2026 showing diastolic improvement in HCM.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month